30 closest matches · ranked by relevance
Diarrhea · Gastroenteritis
Primary: Duration of Diarrhea in Acute Diarrheal Illnesses in a Developed Nation While Taking Zinc or Placebo. — 73; 72; 48; 76.8 Hours — p=0.88
Acute Diarrhoea
Primary: Time to Recovery — 66.0; 68.6 Hours — p==0.2524
Diarrhea, Infantile
Primary: Duration of Diarrhea (Hours) Between the Start of Treatment Until Last Diarrheal/Watery Stool Before Recovery or End of Study Treatment (Treatment Duration Maximal 5…
Diarrhea
Primary: Duration of Diarrhea (Hours) Between the Start of Treatment Until Last Diarrheal/Watery Stool Before Recovery or End of Study Treatment (Treatment Duration Maximal 5…
Diarrhea
Primary: Duration of Diarrhea — 2; 2 days — p=0.43
Diarrhea · Cholera
Primary: Stool Output — 4769; 4742; 1688; 1704 gram — p=0.9941
Cholera
Primary: Stool Output Volume During Treatment Period. — 9.82; 9.31; 5.69; 7.29 ml/kg·h-1 — p=0.003
Diarrhoea
Primary: Time (in Hours) Between the 1st Intake of IQP-MM-101 and First Formed or Hard Stool (Type 6 to 1) Followed by a Non Watery Stool (Type 6 to 1) — 21.30 hours
Diarrhea
Primary: Number of Participants That Were Successfully Rehydrated — 57; 49 Participants — p=0.28
Cholera
Primary: Diarrheal Stool Output Rate — 25.42; 32.57 mL/hour — p=0.2254
Irritable Bowel Syndrome
Primary: Number of Participants With Post Infectious Irritable Bowel Syndrome — 23; 114 participants
Healthy Volunteer
Primary: Incidence of Adverse Events — 1; 1; 0; 1 events
Feasibility Study
Primary: Number of Participants With Stool Sample Acquired — 46 Participants
Chronic Functional Diarrhea of Unknown Origin
Primary: Mean Change From Baseline in Blood Lead Levels During the Treatment Period and Post-treatment Follow-up Period — 0.120; 0.306; 0.095; 0.359 nanograms per millilitre…
Infectious Diarrhoea
Primary: Time to Last Unformed Stool (TLUS) — 59.3; 51.4; 57.4 hours
Diarrhoea;Acute
Primary: Reduction in Frequency of Defecation to 3 Times Per Day — 118; 24 Participants
Antibiotics Associated Colitis · Pulmonary Infection
Primary: Presence of AAD — 12 participants — p=<0.05
Traveler's Diarrhea
Primary: Time to Last Unformed Stool (TLUS) — 44.3; 40.3 hours
Infectious Gastroenteritis
Primary: Analysis of Diarrheal Illness Etiologies Identified in Stool Culture Compared to the FilmArray™ Gastrointestinal (GI) Panel — 434; 19 Participants
Prevention of Travelers' Diarrhea
Primary: Geometric Mean Titer (GMT) After First and Second Vaccination With LT Vaccine Patch and Comparison Against Placebo — 432.6; 400.5; 4477.5; 490.6 geometric mean titer
Gastroenteritis
Primary: Number of Participants With Modified Vesikari Scale Score >=9 — 55; 60 Participants — p=0.83
Diarrhea
Primary: Part A: Number of Serious Adverse Events and Adverse Events Leading to Withdrawal — 0; 0; 0; 0 adverse events
Diarrhea
Primary: Cumulative Occurrence of Travellers' Diarrhea (TD) for Rifaximin 600 mg QD Compared to Placebo Over 14 Days of Treatment — 15; 48 Participants
Appendicitis · Appendicitis; Perforation
Primary: Length of Hospital Stay — 121.55; 131.69 hours
Healthy Volunteer
Primary: Safety of Serum Derived Bovine Immunoglobulins (BSIgG) — 1; 2; 0; 2 Participants
Carcinoma, Non-Small-Cell Lung
Primary: Occurence of CTCAE Grade >= 2 Diarrhea — 72.20; 31.80 Percentage of participants
Breast Cancer
Primary: Diarrhea for >= 2 Consecutive Days — 68; 69.6; 65.2; 72.2 percentage of patients
Diarrhea Bloody
Primary: Blood Test Performance — 18; 17 Participants
Cryptosporidium Infection, Cryptosporidiosis
Primary: Percentage of Participants With Cryptosporidium Infection From 72 Hours to 10 Days Post ABO809 Oral Administration — 50; 57.1; 60.0 percentage of participants
Diarrhea · Gastrointestinal Complications · Unspecified Adult Solid Tumor, Protocol Specific
Primary: Maximum Severity of Diarrhea Toxicity as Measured by the CTCAE v4.0 During and After Radiotherapy (RT) — 10; 10; 13; 15 Participants — p=0.41